- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01616784
The REPOSE (Relative Effectiveness of Pumps Over MDI and Structured Education) Trial (REPOSE)
The Relative Effectiveness of Pumps Over Multiple Dose Injections and Structured Education Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SE5 9RS
- Kings College Hospital, Diabetes Centre, Suite 3, Golden Jubilee Wing, Denmark Hill
-
Nottingham, United Kingdom, NG7 2UH
- Nottingham University Hospitals NHS Trust, Queens Medical Centre Campus, Derby Road
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
- Addenbrookes Wolfson Diabetes and Endocrine Clinic, Box 281, Addenbrookes Hospital, Hills Road
-
-
North Yorkshire
-
Harrogate, North Yorkshire, United Kingdom, HG2 7SX
- Harrogate District Hospital, Diabetes Centre, Lancaster Park Road,
-
-
Scotland
-
Dumfries, Scotland, United Kingdom, DG1 4TG
- Dumfries and Galloway Royal Infirmary, Diabetes Centre, Cluden West, Crichton Hall,
-
Edinburgh, Scotland, United Kingdom, EH16 4SA
- Royal Infirmary of Edinburgh, Department of Diabetes, 51 Little France Crescent
-
Glasgow, Scotland, United Kingdom, G21 3UW
- Stobhill ACH, Diabetes Clinic, 133 Balornock Road
-
-
South Yorkshire
-
Sheffield, South Yorkshire, United Kingdom, S5 7AU
- Sheffield Teaching Hospital, Diabetes Centre, Northern General Hospital, PO Box 1, Herries Road
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is aged 18 yrs and above.
- Have had type-1 diabetes for at least 12 months (as assessed by date clinically diagnosed).
- Is fluent in speaking, reading and understanding English.
- Has no preference to either CSII or MDI arm of the study and is happy to be randomised.
- Is currently using or willing to switch to Detemir.
- Is willing to undertake self-monitoring of blood glucose (SMBG), carbohydrate counting and insulin self-adjustment. (Enrolment staff should check that any participant with a baseline HbA1c of above 12% is willing to complete SMBG).
- Has a need for structured education to optimise diabetes control in the opinion of the investigator.
Exclusion criteria:
- Inability to give informed consent.
- Is pregnant or planning to become pregnant within the next 2 years.
- Has used CSII within the last 3 years.
- Has already completed a diabetes education course.
- Has severe needle phobia.
- Has a current history of alcohol or drug abuse.
- Has a history of heart disease within the past 3 months.
- Has hypertension that is not under control with hypertensive medication (diastolic blood pressure >100mmHg and or sustained systolic level >160).
- Has renal impairment with a chance of needing renal replacement therapy within the next 2 years (Enrolment staff should check that creatinine levels are not above 200 µmol/L).
- Has recurrent episodes of skin infections.
- Has serious or unstable medical or psychological conditions.
- Has taken part in any other investigational clinical trial during the 4 months prior to screening.
- Has any other issue that may preclude the participant from satisfactory participation in the study based on investigatory judgement.
- Has a strong need for pump therapy in the opinion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Multiple daily injections plus DAFNE
Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
|
Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
|
Experimental: CSII (Insulin Pump) plus DAFNE
Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
|
Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in HbA1c after 2 years in those participants whose baseline HbA1c was at or above 7.5% (58mmol/mol).
Time Frame: 2 years
|
The change in HbA1c after 2 years in those participants whose baseline HbA1c was at or above 7.5% (58mmol/mol). (Change will be calculated from baseline at 24 months) |
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of participants reaching the NICE target of an HbA1c level of 7.5% (58mmol/mol) or less
Time Frame: 6, 12 and 24 months
|
HbA1c is a measurement of glycosylated haemoglobin which reflects overall blood glucose values over the previous 6-8 weeks(24). This is regarded as the gold standard measure of glycaemic control. There is a strong relationship between HbA1c and the risk of developing long term diabetic complications and it is accepted as a surrogate for long term outcomes in individuals with diabetes. Since HbA1c can be measured by different techniques we will ensure standardisation by measuring HbA1c in blood samples at a central laboratory. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Diabetes specific quality of life
Time Frame: 6, 12 and 24 months
|
DSQOL Diabetes-specific quality of life (QoL) will be assessed using the scale DSQOL. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Hypoglycaemia (severe & moderate)
Time Frame: 6, 12 and 24 months
|
The investigators will record both severe and moderate episodes of hypoglycaemia in participants. This should increase power and identify the ability of CSII to reduce rates of hypoglycaemia. It will also be possible to assess the effects of both, by comparing quality of life measures in those with only moderate hypos, versus those with moderate and severe. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Insulin dose
Time Frame: 6, 12 and 24 months
|
Some studies have indicated that CSII results in the use of less insulin. We will therefore record participants' self-reported insulin dose at each time point and calculate units/kg body weight. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Body weight
Time Frame: 6, 12 and 24 months
|
If CSII treatment results in the use of less insulin, it may have a favourable effect on weight since with less insulin there is a propensity for the body to store fewer nutrients. We will therefore record weight at each time point of the trial. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Blood lipids & proteinuria
Time Frame: 6, 12 and 24 months
|
Blood samples will be taken using local labs and lipids (including HDL cholesterol). Albumin- creatinine ratio (a sensitive measure of proteinuria) will be measured from urine samples. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Diabetic Ketoacidosis
Time Frame: 6, 12 and 24 months
|
This outcome will be measured through the assessment of any SAE's and AEs. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Fear of hypoglycaemia
Time Frame: 6, 12 and 24 months
|
The Hypoglycaemia Fear Scale (HFS) is a well validated psychometric tool assessing participants fear of hypoglycaemia both overall and in terms of behaviour and worry. It has been used to assess the impacts of different hypoglycaemic events such as severe, moderate and mild hypoglycaemic episodes on fear of hypoglycaemia (33). A specific benefit to the HFS is that it may be able to identify participants who are likely to maintain high blood glucose levels, thus aiding understanding of potential reasons for poor glycaemic control. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Diabetes Treatment Satisfaction
Time Frame: 6, 12 and 24 months
|
The Diabetes Treatment Satisfaction Questionnaire (DTSQ measures treatment satisfaction which refers to an individual's subjective appraisal of their experience of treatment, including ease of use, side effects and efficacy. Improvements in satisfaction are not necessarily accompanied by improvements in QoL; treatment satisfaction can be high despite diabetes having a negative impact on QoL, which is why it is important to measure both separately. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Emotional Wellbeing
Time Frame: 6, 12 and 24 months
|
The Hospital Anxiety and Depression Scale (HADS) measures anxiety on one subscale and depression on another through the use of 7 questions for each characteristic. It is important to measure emotional wellbeing in the trial as participants may find it easier to manage their condition after DAFNE education or with one of the treatments. This might have a substantial effect on their emotional wellbeing that the QoL measures are not sensitive enough to pick up. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Participant views regarding the pump/multiple injection course & treatment
Time Frame: 6, 12 and 24 months
|
Participant post course interviews Participants will be interviewed regarding:
|
6, 12 and 24 months
|
Educator views regarding the pump/multiple injection course & treatment
Time Frame: 6, 12 and 24 months
|
Educator post course interviews Educators will be interviewed regarding: a) Insight and experience of what took place on the course. b) Recommendations for future course development. c) Recommendations for support that should be offered to patients who move onto pumps. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Costs and Outcomes
Time Frame: 6, 12 and 24 months
|
Costs and quality adjusted life years will be estimated for each individual recruited to the trial. Mean values for each arm will be calculated. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Incremental cost-effectiveness ratio
Time Frame: 6, 12 and 24 months
|
Cost-effectiveness will be described using plots of incremental costs and QALYs on the cost-effectiveness plane, together with their associated cost-effectiveness acceptability curves and frontiers. The incremental cost-effectiveness ratio and the probability that CSII will be cost-effective in the range of £20,000-£30,000 per QALY will be the main focus. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Costs
Time Frame: 6, 12 and 24 months
|
Mean values of cost wll be estimated and the value will be calculated for each individual (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
General Quality of Life
Time Frame: 6, 12 and 24 months
|
This will be measured by 3 different measures, the WHOQOL bref, SF12 and EQ5D. (Change will be calculated from baseline at 24 months) |
6, 12 and 24 months
|
Quality of adjusted life years
Time Frame: 6, 12 and 24 months
|
Mean values will be estimated and value will be calculated for each individual (Change will be calculated from baseline at 24 months)
|
6, 12 and 24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Simon Heller, Prof, University of Sheffield
Publications and helpful links
General Publications
- REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ. 2017 Mar 30;356:j1285. doi: 10.1136/bmj.j1285.
- Heller S, White D, Lee E, Lawton J, Pollard D, Waugh N, Amiel S, Barnard K, Beckwith A, Brennan A, Campbell M, Cooper C, Dimairo M, Dixon S, Elliott J, Evans M, Green F, Hackney G, Hammond P, Hallowell N, Jaap A, Kennon B, Kirkham J, Lindsay R, Mansell P, Papaioannou D, Rankin D, Royle P, Smithson WH, Taylor C. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technol Assess. 2017 Apr;21(20):1-278. doi: 10.3310/hta21200.
- Bradburn MJ, Lee EC, White DA, Hind D, Waugh NR, Cooke DD, Hopkins D, Mansell P, Heller SR. Treatment effects may remain the same even when trial participants differed from the target population. J Clin Epidemiol. 2020 Aug;124:126-138. doi: 10.1016/j.jclinepi.2020.05.001. Epub 2020 May 11.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STH15295
- 08/107/01 (Other Grant/Funding Number: HTA)
- 2010-023198-21 (EudraCT Number)
- 11/H1002/10 (Registry Identifier: REC)
- 61215213 (Registry Identifier: ISRCTN)
- 10997 (DRN 628) (Registry Identifier: UKCRN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on MDI (levemir® & quick acting insulin) plus DAFNE
-
Mannkind CorporationJaeb Center for Health ResearchActive, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1United States
-
Nemours Children's ClinicCompletedDiabetes Mellitus, Insulin-DependentUnited States
-
AstraZenecaCompletedType 2 Diabetes MellitusUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1Saudi Arabia